These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 30395214)

  • 1. Reviving Phage Therapy for the Treatment of Cholera.
    Bhandare S; Colom J; Baig A; Ritchie JM; Bukhari H; Shah MA; Sarkar BL; Su J; Wren B; Barrow P; Atterbury RJ
    J Infect Dis; 2019 Feb; 219(5):786-794. PubMed ID: 30395214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cocktail of three virulent bacteriophages prevents Vibrio cholerae infection in animal models.
    Yen M; Cairns LS; Camilli A
    Nat Commun; 2017 Feb; 8():14187. PubMed ID: 28146150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Tail Fiber Protein and a Receptor-Binding Protein Mediate ICP2 Bacteriophage Interactions with Vibrio cholerae OmpU.
    Lim ANW; Yen M; Seed KD; Lazinski DW; Camilli A
    J Bacteriol; 2021 Jun; 203(13):e0014121. PubMed ID: 33875544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of cocktail phage therapy in treating Vibrio cholerae infection in rabbit model.
    Jaiswal A; Koley H; Ghosh A; Palit A; Sarkar B
    Microbes Infect; 2013 Feb; 15(2):152-6. PubMed ID: 23159467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EFFECT OF MUKERJEE'S GROUP IV PHAGE ON EL TOR VIBRIOS.
    MONSUR KA; RIZVI SS; HUQ MI; BENENSON AS
    Bull World Health Organ; 1965; 32(2):211-6. PubMed ID: 14310908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenic potential of vibriophages against an experimental infection with Vibrio cholerae O1 in the RITARD model.
    Bhowmick TS; Koley H; Das M; Saha DR; Sarkar BL
    Int J Antimicrob Agents; 2009 Jun; 33(6):569-73. PubMed ID: 19157799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolutionary consequences of intra-patient phage predation on microbial populations.
    Seed KD; Yen M; Shapiro BJ; Hilaire IJ; Charles RC; Teng JE; Ivers LC; Boncy J; Harris JB; Camilli A
    Elife; 2014 Aug; 3():e03497. PubMed ID: 25161196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of different oral approaches to treat Vibrio cholerae infection in adult mice.
    Jaiswal A; Koley H; Mitra S; Saha DR; Sarkar B
    Int J Med Microbiol; 2014 May; 304(3-4):422-30. PubMed ID: 24656386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the role of bacteriophage in the control of cholera outbreaks.
    Jensen MA; Faruque SM; Mekalanos JJ; Levin BR
    Proc Natl Acad Sci U S A; 2006 Mar; 103(12):4652-7. PubMed ID: 16537404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diminished diarrheal response to Vibrio cholerae strains carrying the replicative form of the CTX(Phi) genome instead of CTX(Phi) lysogens in adult rabbits.
    Faruque SM; Rahman MM; Hasan AK; Nair GB; Mekalanos JJ; Sack DA
    Infect Immun; 2001 Oct; 69(10):6084-90. PubMed ID: 11553546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemolytic Vibrio cholerae O1 that is sensitive to Mukerjee's cholera phage IV and the phage produced by the hemolytic vibrio lysogenized with the infection of Mukerjee's cholera phage IV.
    Iwanaga M; Nakamura S; Kuyyakanond T
    Microbiol Immunol; 1989; 33(8):609-18. PubMed ID: 2779469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108.
    Liang W; Wang S; Yu F; Zhang L; Qi G; Liu Y; Gao S; Kan B
    Infect Immun; 2003 Oct; 71(10):5498-504. PubMed ID: 14500467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional Analysis of Bacteriophage Immunity through a Type I-E CRISPR-Cas System in Vibrio cholerae and Its Application in Bacteriophage Genome Engineering.
    Box AM; McGuffie MJ; O'Hara BJ; Seed KD
    J Bacteriol; 2016 Feb; 198(3):578-90. PubMed ID: 26598368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of the evolutionary arms race between Vibrio cholerae and Vibriophage clinical isolates.
    Yen M; Camilli A
    Int Microbiol; 2017 Sep; 20(3):116-120. PubMed ID: 29446802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of the lysogenic phage encoding cholera toxin in naturally occurring strains of toxigenic Vibrio cholerae O1 and O139.
    Faruque SM; Asadulghani ; Alim AR; Albert MJ; Islam KM; Mekalanos JJ
    Infect Immun; 1998 Aug; 66(8):3752-7. PubMed ID: 9673258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mode of action of bacteriophage phi 149 on cholera and El Tor vibrios.
    Maiti M
    Can J Microbiol; 1978 Dec; 24(12):1583-9. PubMed ID: 747818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phage for treatment of Vibrio cholerae infection.
    Mittal M; Tripathi S; Saini A; Mani I
    Prog Mol Biol Transl Sci; 2023; 201():21-39. PubMed ID: 37770173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [POSSIBILITIES OF APPLICATION OF MALDI-TOF MASS-SPECTROMETRY FOR STUDY OF CARBOHYDRATE-SPECIFIC RECEPTORS FOR DIAGNOSTIC BACTERIOPHAGE EL TOR].
    Telesmanich NR; Goncharenko EV; Chaika SO; Chaika IA; Telicheva VO
    Zh Mikrobiol Epidemiol Immunobiol; 2016; (2):85-90. PubMed ID: 27228677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presence of lysogenic phage in the outbreak strains of Vibrio cholerae O139.
    Mitra SN; Kar S; Ghosh RK; Pajni S; Ghosh A
    J Med Microbiol; 1995 Jun; 42(6):399-403. PubMed ID: 7791203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vibrio cholerae serogroup O1 in northeast Thailand.
    Kuyyakanond T; Nakamura S; Manmontri W; Iwanaga M
    J Clin Microbiol; 1990 May; 28(5):872-5. PubMed ID: 2191009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.